Two different approaches to the same idea of raising NAD availability. 5-Amino-1MQ blocks the enzyme that consumes its precursor; NAD protocols supply the molecule directly. One of them has never been given to a human in a published study.
Side by side
| 5-Amino-1MQ | NAD+ | |
|---|---|---|
| Class | NNMT inhibitor (small molecule, not a peptide) | Cellular coenzyme |
| Status | Research compound | Not a peptide; compounded and gray-market injectable |
| Route | Oral (typical) or subcutaneous | Subcutaneous injection |
| Typical vials | 50 mg, 100 mg | 100 mg, 500 mg, 1,000 mg |
| Dose range | 25 mg to 50 mg | 25 mg to 100 mg |
| Frequency | Daily | 2 to 3 times weekly |
| Half-life | No human data | No human data |
| Dosing unit | milligrams | milligrams |
Pharmacokinetics
No curves are shown, on purpose.
No published human pharmacokinetics for 5-Amino-1MQ or NAD+. Drawing one curve against an absent one would imply a comparison that cannot be made.
What the evidence supports
These grade how well each outcome has been studied in humans, never how well either compound works. A strong grade can sit on a negative result.
The strongest evidence for any claimed outcome is Human RCT for NAD+ and Animal only for 5-Amino-1MQ. That gap is the most important line on this page.
5-Amino-1MQ
| Outcome | Evidence |
|---|---|
| Fat mass reduction | Animal only |
| Muscle function in aged animals | Animal only |
| NNMT inhibition | Mechanistic only |
| Any outcome in humans | No data |
NAD+
| Outcome | Evidence |
|---|---|
| Clinical outcomes from precursor supplementation | Human RCT |
| Precursor supplementation raises blood NAD+ | Human RCT |
| Addiction or withdrawal treatment | No data |
| Outcomes from injected or infused NAD+ | No data |
How to choose
5-Amino-1MQ has no human trials of any kind
Mouse and cell work only. It is also not a peptide, it is a small molecule NNMT inhibitor.
NAD at least has human trials, of precursors
Which is a real caveat, but it is more than zero.
Both rest on the same unproven step
That raising NAD availability in humans produces the metabolic effects seen in mice.
At the syringe
At the default setup on each compound's own page, a 50 mg vial in 2 mL puts 250 mcg on every insulin unit, while a 500 mg vial in 5 mL puts 1 mg on every unit. That is the number that decides whether a dose lands on a readable mark, and it is set by how much water goes in, not by the compound.